Publication Name	World Journal of Clinical Cases
Manuscript ID	88795
Country	Japan

Received	2023-10-11 05:39
Peer-Review Started	2023-10-11 05:41
To Make the First Decision
Return for Revision	2023-10-24 06:34
Revised	2023-11-04 11:27
Second Decision	2023-11-21 03:53
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2023-11-30 05:03
Articles in Press	2023-11-30 05:03
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2023-12-06 16:01
Publish the Manuscript Online	2023-12-14 06:01

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Case Report
Article Title	Abemaciclib-induced lung damage leading to discontinuation in brain metastases from breast cancer: A case report
Manuscript Source	Unsolicited Manuscript
All Author List	Hiroyasu Yamashiro and Nao Morii
ORCID	Author(s) ORCID Number Hiroyasu Yamashiro http://orcid.org/0000-0003-1778-6735
Funding Agency and Grant Number
Corresponding Author	Hiroyasu Yamashiro, MD, PhD, Director, Department of Breast Surgery, Tenri Hospital, No. 200 Mishima-cho, Tenri 632-8552, Nara, Japan. yamashiro.bcs@gmail.com
Key Words	Breast cancer; HER2 negative; Brain metastasis; Abemaciclib; Drug-induced interstitial lung damage; Case report
Core Tip	In this case report, we address the critical issue of limited therapeutic options for HER2-negative breast cancer patients with brain metastases. We present a case of a woman with estrogen receptor-positive, HER2-negative breast cancer who initially exhibited an encouraging response to abemaciclib and letrozole therapy for brain metastases. However, this treatment had to be discontinued due to drug-induced lung damage. This study reports the challenges of achieving a balance between efficacy and adverse events in managing brain metastases and highlights the need for alternative treatment strategies in this patient population.
Publish Date	2023-12-14 06:01
Citation	Yamashiro H, Morii N. Abemaciclib-induced lung damage leading to discontinuation in brain metastases from breast cancer: A case report. World J Clin Cases 2023; 11(35): 8425-8430
URL	https://www.wjgnet.com/2307-8960/full/v11/i35/8425.htm
DOI	https://dx.doi.org/10.12998/wjcc.v11.i35.8425

Full Article (PDF)	WJCC-11-8425-with-cover.pdf
Full Article (Word)	WJCC-11-8425.docx
CARE Checklist–2016	88795-CARE Checklist (2016).pdf
Manuscript File	88795_Auto_Edited-JLW.docx
Answering Reviewers	88795-Answering reviewers.pdf
Audio Core Tip	88795-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	88795-Conflict-of-interest statement.pdf
Copyright License Agreement	88795-Copyright license agreement.pdf
Signed Consent for Treatment Form(s) or Document(s)	88795-Informed consent statement.pdf
Non-Native Speakers of English Editing Certificate	88795-Language certificate.pdf
Peer-review Report	88795-Peer-review(s).pdf
Scientific Misconduct Check	88795-Bing-Qu XL-2.jpg
Scientific Editor Work List	88795-Scientific editor work list.pdf